PTEN and B-cell chronic lymphocytic leukemia: PI3Kβ-selective inhibitors have been proposed in the treatment of PTEN-deficient tumors [9,10,11], while PI3Kδ inhibitors are currently under evaluation in clinical trials for the treatment of some specific lymphoproliferative diseases including chronic lymphocytic leukemia (CLL), multiple myeloma, and Hodgkin’s lymphoma [12,13,14,15].